Moximed's technology, the MISHA Knee System, is the result of over a decade of clinical research and development and is the first implantable shock absorber for the treatment of medial compartment knee osteoarthritis (OA). With experienced med-tech leadership and strong investor support, Moximed is poised to elevate the standard of care and quality of life for millions of pre-arthroplasty knee OA sufferers hindered by arthritic knee pain and function loss.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
08/13/24	$91,000,000	Series D	Advent Life Sciences Cormorant Asset Management Elevage Medical Technologies Future Fund GBS Venture Partners Gilde Healthcare Partners Morgenthaler New Enterprise Associates Vertex Ventures Warren Point Capital	undisclosed